[ACCESSWIRE]
ADDISON, TX / ACCESSWIRE / January 13, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company has appointed John Siedhoff to its Board of Directors.
John Siedhoff earned a Bachelor of Science Degree in Mechanical Engineering from Iowa State University. Siedhoff spent the next 12 years working for Fluor Corporation and Controls Southeast, Inc., in the design, manufacture and installation of high temperature, high pressure piping systems for oil refineries and petrochemical plants, both foreign and domestic.
Siedhoff's turnaround and merger and acquisition experience started as Chief Operating Officer of Enduro Systems, Inc., acquiring companies to vertically integrate material handling operations for the weighing, conveying, and filling of oil refined products, to the rapid loading of grain.
Siedhoff has been a part of a consortium acquiring more than twenty companies with a specific focus and expertise on turnaround opportunities and has led the effort to take companies public through reverse merger transactions.
Robert Lutz, Jr, Chief Executive Officer of Wound Management Technologies, comments, "We are excited to have John Siedhoff join our Board of Directors. With the recent appointments of Dr. Ronald Goode and Jeffrey Lewis, John's appointment only further strengthens the stellar board that we have put in place. We will look to draw from the team's expertise and background but specifically John's business and transaction history."
"I look forward to working with the industry leading board members that Wound Management has assembled and advising the company as it continues to advance and execute on its strategic growth initiatives for the good of our shareholders," comments Mr. Siedhoff.
About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.
To download Wound Management Technologies' investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.
Information about Forward-Looking Statements
The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Investor Contacts:
KCSA Strategic Communications
Todd Fromer / Garth Russell
+ 212-682-6300
[email protected] / [email protected]
SOURCE: Wound Management Technologies, Inc.
